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Introduction: Macrocyclic diterpenes from Euphorbia species were found to be
promising modulators of multidrug resistance (MDR), a complex phenomenon that
hampers the effectiveness of cancer therapy.
Objective: To find new effective MDR reversers through the phytochemical study
of E. boetica, including isolation and molecular derivatisation.
Material and methods: The phytochemical study of E. boetica was performed
through chromatographic techniques. Preliminary analysis of crude chromatographic
fractions from the methanol extract was carried out by 1H‐NMR in order to prioritise
the study of those having macrocyclic diterpenes. Polyamide resin was used to
remove chlorophylls. Molecular derivatisation of isolated compounds comprised
hydrolysis, reduction and acylation reactions. The structural identification of
compounds was performed through analysis of spectroscopic data, mainly one‐
dimensional‐ and two‐dimensional‐NMR. The MDR reversing activity was assessed
using a combination of transport and chemosensitivity assays, in mouse lymphoma
(L5178Y‐MDR) and Colo320 cell models.
Results: The 1H‐NMR study of crude fractions and application of a straightforward
method to remove chlorophylls, allowed the effortless isolation of two lathyrane‐type
diterpenes in large amounts, including the new polyester, euphoboetirane B (1).
Taking advantage of the chemical functions of 1, 13 new derivatives were prepared.
Several compounds showed to be promising modulators of P‐glycoprotein (P‐gp), in
resistant cancer cells. Most of the compounds tested revealed to interact synergisti-
cally with doxorubicin.
Conclusion: These results corroborate the importance of macrocyclic lathyrane
diterpenes as effective lead compounds for the reversal of MDR.
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NETO ET AL. 4991 | INTRODUCTION
Euphorbia species (Euphorbiaceae) are reported to be used in traditional
medicine to treat skin cancer and warts, digestive system disorders and
infections.1 Importantly, topical administration of E. peplus sap in Aus-
tralian folk medicine prompted the development of Picato® (ingenol
mebutate) gel, approved in 2012 by the US Food and Drug Administra-
tion (FDA) for the treatment of actinic keratosis.2 In the last decades,
Euphorbia species have been the subject of intensive phytochemical
studies that have resulted in the isolation of a high diversity of com-
pounds, some of them exhibiting very important biological activities.3,4
In particular, these species have afforded a large number of structurally
uniquemacrocyclic diterpeneswith the lathyrane and jatrophane skele-
tons.4,5 Apart from their importance as biogenetic and chemotaxonomic
markers, since they are exclusively isolated fromEuphorbiaceae plants,6
several studies have revealed that they are promising modulators of
multidrug resistance (MDR) in tumour cells.4,5,7-14
Currently, resistance towards many clinically used drugs is a major
limitation to effective cancer therapies.15-17 Cancer resistance can be
broadly divided as intrinsic, when the tumour fails to respond to the
initial chemotherapy, and acquired during treatment by various
therapy‐induced adaptive responses.16,18 Resistance could also take
more complex outcomes when treatments fail to respond to multiple
drugs with different mechanisms of action, a phenomenon referred as
multidrug resistance (MDR).19 There are several mechanisms responsi-
ble for MDR, which have been exhaustively reviewed.15,17,18,20-22 By
far, the most studied mechanisms are related with the overexpression
of several efflux membrane proteins. Among them, the ATP‐Biding‐
Cassete (ABC) superfamily largely contributes to MDR, resulting in
the increased translocation of the cytotoxic drugs out of the cell,
consequently reducing their intracellular concentrations and their
biological effect.15,19,21
In mammalian cells, three main ABC transporter proteins are
involved in MDR: P‐glycoprotein (P‐gp/MDR1/ABCB1), the multidrug
resistant associated protein (MRP1/ABCC1) and the breast cancer
resistant protein (BCRP/ABCG2).19,21 P‐gp has been exhaustively stud-
ied, and until date, some of the most significant strategies to overcome
MDR target this efflux transporter. One pharmacological approach
involves the co‐administration of a non‐toxic P‐gp modulator and the
cytotoxic agent, in order to inhibit or modulate its efflux, increasing
the concentration of drugs within the cells.19-21 Many synthetic and
natural P‐gp modulators have been reported, and some of them have
reached the stage of clinical trials. However, only limited success was
achieved and more studies to find new non‐toxic and effective P‐gp
modulators are still of great significance.23,24 In addition, in recent
years considerable progresses have been made on knowledge about
mechanistic and functional aspects of ABC transporters, not only to
define their substrates and inhibitors,21 but also to characterise P‐gp
structure at near‐atomic resolution providing molecular basis for addi-
tional conformations and drug binding modes and sites.23
Continuing our research for novel MDR modulators from natural
sources, herein, we report the isolation of two lathyrane diterpene
polyesters (1 and 2), from Euphorbia boetica aerial parts, one of them(1) isolated for the first time. The straightforward and timeless isola-
tion of compounds was only possible thanks to the use preliminary
1H‐NMR analysis of crude fractions, and removal of chlorophylls
through flash chromatography over polyamide. Aiming at obtaining a
set of homologous bioactive compounds, diterpene 1, isolated in high
quantity, was submitted to several chemical transformations, including
hydrolysis, reduction and acylation reactions. Overall, 13 derivatives
(3–15) were obtained, and characterised using spectroscopic methods.
Their effect on modulation of P‐gp efflux was evaluated by flow
cytometry, measuring the rhodamine‐123 accumulation in MDR
mouse T‐lymphoma cells and MDR human colon adenocarcinoma
(Colo 320) cells. Furthermore, some of these modulators were
assayed, in vitro, for their effects in combination with doxorubicin.2 | EXPERIMENTAL SECTION
2.1 | General procedures
All solvents were dried according to published methods and distilled
prior to use. All the other reagents were obtained from commercial sup-
pliers and were used without further purification. Flash column chro-
matography (CC) was performed on polyamide CC 6 (0.05–0.16 mm,
Macherey‐Nagel) and silica gel (Merck 9385), or by using CombiFlash®
Rf200 (Teledyne Isco). Merck silica gel 60 F254 plates were used in
analytical thin‐layer chromatography (TLC), with visualisation under
ultraviolet (UV) light (λ = 254 and 366 nm) and by spraying with
sulphuric acid/methanol (H2SO4/MeOH) (1:1), followed by heating.
For preparative TLC, 20 cm × 20 cm silica plates were used (Merck
1.05774). Melting points were determined on a Köpffler apparatus.
Specific optical rotations α½ 25D were obtained on a Perkin‐Elmer 241‐
MC polarimeter using quartz cells of 1 dm path length, and all samples
were solubilised in chloroform (CHCl3). Infrared (IR) spectra were deter-
mined on a Shimadzu IRAffinity‐1 FTIR spectrophotometer. Nuclear
magnetic resonance (NMR) spectra were recorded on a Brüker ARX‐
400 NMR spectrometer (1H 400 MHz; 13C 100.61 MHz), using CDCl3,
CD3OD, C5D5N or DMSO‐d6 as solvents. Chemical shifts are expressed
in δ (ppm) referenced to the solvent used, and the proton coupling con-
stants J in hertz (Hz). Spectra were assigned using appropriate COSY,
DEPT, HMQC and HMBC sequences. High‐resolution mass spectra
were recorded on a FTICR‐MSApex Ultra (Brüker Daltonics) 7 T instru-
ment. Electrospray ionisation mass spectrometry (ESI‐MS) analysis
were performed on a triple quadrupole (QT) Micromass Quattro Micro
AP1 mass spectrometer, with an ESI ion source set in a positive
ionisation mode. All tested compounds were purified to ≥ 95% purity
as determined by high‐performance liquid chromatography (HPLC).2.2 | Phytochemical study
Euphorbia boetica Boiss. (Euphorbiaceae) aerial parts were extracted
with MeOH as previously reported.8 Briefly, the air‐dried aerial parts
were exhaustively extracted with MeOH at room temperature. The
pooled extracts were evaporated under vacuum to give a residue that
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ethyl acetate (EtOAc). Chromatographic fractionation of the EtOAc
soluble part of the MeOH extract afforded 10 crude fractions (A–J).
To perform preliminary 1H‐NMR experiments, 15 mg of each fraction
were solubilised in 650 μL of CDCl3, filtered, and further analysed
aiming at prioritising the study of those fractions having macrocyclic
diterpenes.Fraction E (58.2 g) obtained with n‐hexane/EtOAc (7:3)
was chromatographed on a polyamide column (300 g) with mixtures
of MeOH/H2O (1:1, 3:2, 7:3, 4:1 and 1:0) as eluents. The Fraction
obtained with MeOH/H2O (3:2 and 7:3, 24.8 g) was subjected to silica
gel flash chromatography [silicaon dioxide (SiO2), 300 g], using a gradi-
ent of n‐hexane/EtOAc (1:0 to 0:1) and EtOAc/MeOH (1:0 to 3:1). As
indicated by TLC, and according to differences in composition, 12
fractions were obtained (EA–EL). Fractions EB, EC, ED, EE, EG and EH
were recrystallised from EtOAc/n‐hexane to give: euphoboetirane B
(1, 1.88 g) and 2 (Euphorbia Factor L15, herein named euphoboetirane
A, 1.72 g). The residue of fraction EF (2.63 g) and the mother liquors of
fraction EE (1.69 g) were combined and chromatographed over SiO2
(200 g) using mixtures of n‐hexane/EtOAc (1:0 to 0:1) to obtain six
fractions (EEF1a to EEF1f). The residue of fraction EEF1b (1.52 g) was
recrystallised with EtOAc/n‐hexane to obtain 740 mg of the already
isolated compound 2.
Euphoboetirane B; 5α,15β‐diacetoxy‐3β‐propanoyloxy‐lathyr‐
6(17),12E‐en‐14‐one (1): white crystals (EtOAc/n‐hexane); m.p. 168–
171°C; α½ 25D + 213.0 (c 0.100, CHCl3); IR (KBr): υmax 2969, 1736,
1674, 1624, 1373, 1227, 907 cm−1; 1H‐NMR (400 MHz, CDCl3): δ
0.87 (3H, d, J = 6.7 Hz, CH3‐16), 1.12 (3H, s, CH3‐19), 1.12 (3H, t,
J = 7.4 Hz, 3‐OCOCH2CH3), 1.14 (3H, s, CH3‐18), 1.12 (1H, m, H‐9),
1.36 (1H, dd, J = 8.2, 11.4 Hz, H‐11), 1.56 (1H, dd, J = 11.6,14.4 Hz,
H‐1β), 1.66 (3H, s, CH3‐20), 1.74 (1H, m, H‐8a), 1.94 (3H, s, 5‐OCOC-
H3), 2.00 (1H, m, H‐7b), 2.04 (1H, m, H‐8b), 2.06 (3H, s, 15‐OCOCH3),
2.20 (1H, m, H‐7a), 2.27 (1H, m, H‐2), 2.32 (2H, m, 3‐OCOCH2CH3),
2.75 (1H, dd, J = 3.4, 10.2 Hz, H‐4), 3.42 (1H, dd, J = 8.4, 14.4 Hz, H‐
1α), 4.70 (1H, s, H‐17a), 4.96 (1H, s, H‐17b), 5.57 (1H, t, J = 3.2 Hz,
H‐3), 6.05 (1H, d, J = 10.3 Hz, H‐5), 6.46 (1H, d, J = 11.4 Hz, H‐12);
13C‐NMR (100.61 MHz, CDCl3): δ 9.1 (3‐OCOCH2CH3), 12.5 (C‐20),
14.2 (C‐16), 16.9 (C‐19), 21.3 (5‐OCOCH3), 21.7 (C‐8), 22.1 (15‐
OCOCH3), 25.4 (C‐10), 27.9 (3‐OCOCH2CH3), 28.5 (C‐11), 29.1 (C‐
18), 35.1 (C‐7), 35.5 (C‐9), 37.4 (C‐2), 48.5 (C‐1), 52.4 (C‐4), 65.9 (C‐
5), 80.1 (C‐3), 92.5 (C‐15), 115.6 (C‐17), 134.3 (C‐13), δ 144.5 (C‐6),
146.8 (C‐12), 169.9 (15‐OCOCH3), 170.6 (5‐OCOCH3), 173.9 (3‐
OCOCH2CH3), 197.0 (C‐14); ESI‐MS m/z 475 [M + H]
+. HR‐ESI‐MS:
m/z 475.26163 [M + H]+ (calcd for C27H39O7: 475.26175).
Euphoboetirane A (Euphorbia Factor L15, 2): white crystals (EtOAc/
n‐hexane); m.p. 138–140°C; α½ 25D + 230.0 (c 0.117, CHCl3); IR (KBr):
υmax 2934, 1736, 1644, 1613, 1375, 905 cm
−1; ESI‐MS m/z 461
[M + H]+.252.3 | Preparation of 14β‐hydroxylathyrane (3)
Euphoboetirane B (1, 0.33 mmol) was dissolved in dry terahydrofuran
(THF, 5 mL) and the solution was cooled at 0°C. Lithium aluminiumhydride (LiAlH4) (0.1 mol) was added and the mixture was stirred for
1 h at 0°C. The reaction was stopped with aqueous sodium hydroxide
(NaOH) (10%, 1.5 mL) and stirred for 10 min to neutralise the excess
of LiAlH4. The obtained precipitate was filtrated through celite with
EtOAc/H2O 20% (m/v, 100 mL) and the aqueous layer was extracted
with EtOAc (8 × 20 mL). The organic layers were dried with anhydrous
sodium sulphate (Na2SO4), and evaporated to give an oil that was sub-
jected to column chromatography (SiO2, 12 g, n‐hexane/EtOAc 1:0 to
0:1, CombiFash system) to give 56 mg of a white powder (0.17 mmol,
52% yield).
14β‐Hydroxylathyrane, 3β,5α,14β,15β‐tetrahydroxy‐lathyr‐6
(17),12E‐ene (3): α½ 25D ‐134 (c 0.100, CHCl3); IR (KBr) υmax 3387,
2930, 1627, 1240, 922 cm−1; 1H‐NMR (400 MHz, CDCl3): δ 0.87
(1H, m, H‐9), 0.94 (1H, m, H‐8b), 1.07 (3H, d, J = 4.4 Hz, H‐16), 1.13
(3H, s, H‐18), 1.07 (3H, s, H‐19), 1.32 (1H, dd, J = 8.4, 10. 0 Hz, H‐
11), 1.59 (1H, m, H‐7b), 1.66 (1H, m, H‐8a), 1.70 (3H, s, H‐20), 1.74
(1H, m, H‐4), 1.78 (1H, m, H‐1β), 1.91 (1H, m, H‐2), 2.32 (1H, m, H‐
1α), 2.39 (1H, m, H‐7a), 4.21 (1H, t, J = 3.2 Hz, H‐3), 4.24 (1H, s, H‐
14), 4.91 (1H, s, H‐17a), 4.92 (1H, d, J = 6.0 Hz, H‐5), 5.06 (1H, s, H‐
17b), 5.80 (1H, d, J = 10.8 Hz, H‐12); 13C‐NMR (100.61 MHz, CDCl3):
δ 14.4 (C‐16), 15.5 (C‐19), 16.2 (C‐20), 22.2 (C‐10), 23.9 (C‐8), 24.6 (C‐
11), 29.1 (C‐18), 33.0 (C‐9), 34.5 (C‐7), 36.8 (C‐2), 48.2 (C‐1), 48.8 (C‐
4), 71.5 (C‐5), 77.8 (C‐14), 78.2 (C‐3), 84.6 (C‐15), 109.1 (C‐17), 122.8
(C‐12), 132.8 (C‐13), 150.6 (C‐6); ESI‐MS m/z 359 [M + Na]+, 375
[M + K]+.2.4 | Preparation of lathyrol (4)
Compound 1 (1.52 mol) in MeOH/KOH (potassium hydroxide) (5%)
was stirred for 3 h at room temperature. The reaction was worked
up by dilution with water (20 mL) and extraction with EtOAc (8 × 20
mL). The organic layers were dried with Na2SO4, evaporated and puri-
fied by column chromatography (12 g, n‐hexane/EtOAc 1:0 to 0:1,
CombiFlash system), and further recrystallisation with EtOAc/n‐hex-
ane to give 390 mg of 4 (1.18 mol, yield 78%). Lathyrol, 3β,5α,15β‐
trihydroxy‐lathyr‐6 (17),12E‐en‐14‐one (4): m.p. 174–176°C (EtOAc/n‐
hexane); α½ 25D + 116.0 (c 0.100, CHCl3); IR (KBr): υmax 3414, 1640,
1622, 1411, 1269, 909 cm−1; ESI‐MS m/z 335 [M + H]+. This
compound was identified by comparison of the obtained NMR spec-
troscopic data with literature values.262.5 | General preparation of lathyrol derivatives
A solution of lathyrol (4) in dry triethylamine and dichloromethane
(CH2Cl2) (1:1) was stirred for 5 min at room temperature before addi-
tion of the appropriate acyl chloride or anhydride and a catalytic
amount of 4‐dimethylaminopyridine (DMAP). The mixture was stirred
for 2–18 h, at room temperature or under reflux (60°C, nitrogen atmo-
sphere). The reaction mixture was concentrated under vacuum at
40°C and the obtained residue was purified by flash column chroma-
tography, preparative TLC or HPLC.
NETO ET AL. 5012.5.1 | Preparation of euphoboetirane C (5)
Obtained from reaction of 4 (21 mg, 0.060 mmol) with 70 μL
(0.71 mmol) of 2‐furoyl chloride. The mixture was purified by CC
(SiO2, 4 g, n‐hexane/EtOAc (1:0 to 0:1), Combiflash system) and pre-
parative TLC (n‐hexane/EtOAc, 7:3) to afford 25 mg (0.046 mmol,
77% yield) of an amorphous white powder. α½ 25D + 128 (c 0.100,
CHCl3);
1H‐NMR (400 MHz, CDCl3): δ 1.00 (3H, d, J = 6.7 Hz, CH3‐
16), 1.16 (3H, s, CH3‐19), 1.20 (1H, m, H‐9), 1.22 (3H, s, CH3‐18),
1.44 (1H, dd, J = 8.7, 11.5 Hz, H‐11), 1.68 (1H, m, H‐1β), 1.84 (3H,
s, CH3‐20), 1.92 (1H, m, H‐7b), 2.26 (1H, m, H‐7a), 2.40 (1H, m, H‐
2), 2.86 (1H, dd, J = 3.2, 10.0 Hz, H‐4), 3.14 (1H, m, H‐1α), 4.95 (1H,
s, H‐17a), 4.97 (1H, s, H‐17b), 5.79 (1H, t, J = 3.2 Hz, H‐3), 6.14 (1H,
d, J = 9.9 Hz, H‐5), 6.43 (1H, dd, J = 1.6, 3.3 Hz, H‐4′), 6.48 (1H, dd,
J = 1.6, 3.3 Hz, H‐4″), 7.01 (1H, d, J = 3.2 Hz, H‐3″), 7.12 (1H, d,
J = 3.0 Hz, H‐3′), 7.48 (1H, s, H‐5″), 7.55 (1H, s, H‐5′); 13C‐NMR
(100.61 MHz, CDCl3): δ 13.2 (C‐20), 16.3 (C‐16, C‐19), 25.9 (C‐10),
28.6 (C‐11), 29.0 (C‐18), 36.3 (C‐9), 37.6 (C‐2), 49.6 (C‐1), 52.6 (C‐4),
69.2 (C‐5), 81.2 (C‐3), 115.0 (C‐17), 111.9 (C‐4″), 112.1 (C‐4′), 118.3
(C‐3″), 118.5 (C‐3′), 134.8 (C‐13), 144.2 (C‐2′), 144.0 (C‐2″), 144.4
(C‐6), 145.6 (C‐5′), 146.5 (C‐5″), 157.5 (C‐1″), 157.9 (C‐1′); ESI‐MS
m/z 545 [M + Na]+, 561 [M + K]+.2.5.2 | Preparation of euphoboetirane D (6)
Obtained from reaction of 4 (25 mg, 0.075 mmol) with 70 μL
(0.65 mmol) of 2‐thiophenecarbonyl chloride. The residue was puri-
fied by CC [SiO2, 4 g, n‐hexane/EtOAc (1:0 to 0:1), Combiflash sys-
tem] and preparative TLC (n‐hexane/EtOAc 7:3) to give 26 mg
(0.046 mmol, 61% yield) of an amorphous white powder. α½ 25D +
189 (c 0.090, CHCl3);
1H‐NMR (400 MHz, CDCl3): δ 1.02 (3H, d,
J = 6.7 Hz, CH3‐16), 1.22 (3H, s, CH3‐18), 1.16 (3H, s, CH3‐19),
1.23 (1H, m, H‐9), 1.45 (1H, dd, J = 9.0, 11.1 Hz, H‐11), 1.70 (1H,
m, H‐1β), 1.87 (3H, s, CH3‐20), 2.42 (1H, m, H‐2), 2.86 (1H, dd,
J = 3.2, 10.1 Hz, H‐4), 3.12 (1H, m, H‐1α), 4.95 (1H, s, H‐17a),
5.00 (1H, s, H‐17b), 5.79 (1H, t, J = 3.2 Hz, H‐3), 6.16 (1H, d,
J = 9.8 Hz, H‐5), 7.01 (1H, t, J = 4.3 Hz, H‐4″), 7.07 (1H, t,
J = 4.2 Hz, H‐4′), 7.49 (1H, d, J = 4.9 Hz, H‐3″), 7.53 (1H, d,
J = 4.9 Hz, H‐3′), 7.58 (1H, d, J = 3.1 Hz, H‐5″), 7.67 (1H, d,
J = 4.8 Hz, H‐5′); 13C‐NMR (100.61 MHz, CDCl3): δ 13.2 (C‐20),
14.7 (C‐16), 16.3 (C‐19), 25.9 (C‐10), 28.5 (C‐11), 29.0 (C‐18), 36.4
(C‐9), 37.8 (C‐2), 49.8 (C‐1), 52.6 (C‐4), 80.4 (C‐3), 86.9 (C‐15),
114.7 (C‐17), 123.2 (C‐2′), 123.5 (C‐2″), 127.7 (C‐4″), 127.9 (C‐4′),
132.5 (C‐3″), 132.7 (C‐3′), 133.6 (C‐5″), 133.7 (C‐5′), 134.7 (C‐13),
144.1 (C‐6), 161.1 (C‐1″), 161.4 (C‐1′). ESI‐MS m/z 577 [M + Na]+,
593 [M + K]+.2.5.3 | Preparation of euphoboetirane E (7) and 12‐
hydroxyboetirane A (12)
Obtained from reaction of 4 (24 mg, 0.073 mmol) with 83 mg
(0.44 mmol) of 2‐naphtoyl chloride. The residue was purified by CC[SiO2, 4 g, n‐hexane/EtOAc (1:0 to 0:1), Combiflash system] and pre-
parativeTLC (n‐hexane/EtOAc 4:1, 2×) to give 19 mg of 7 (0.039 mmol,
54% yield) and 6 mg of 12 (0.012 mmol, 16% yield) as amorphous
white solids.Euphoboetirane E (7): α½ 25D + 102 (c 0.100, CHCl3); 1H‐
NMR (400 MHz, CDCl3): δ 1.11 (3H, d, J = 6.8 Hz, CH3‐16), 1.17
(3H, s, CH3‐18), 1.22 (1H, m, H‐9), 1.23 (3H, s, CH3‐19), 1.46 (1H,
dd, J = 8.7, 11.4 Hz, H‐11), 1.63 (1H, m, H‐8a), 1.68 (1H, m, H‐1β),
1.83 (3H, s, CH3‐20), 1.96 (1H, m, H‐8b), 1.97 (1H, m, H‐7b), 2.20
(1H, m, H‐2), 2.30 (1H, m, H‐7a), 2.64 (1H, dd, J = 1.7, 10.1 Hz, H‐
4), 3.11 (1H, m, H‐1α), 3.15 (1H, s, 3‐OH), 4.21 (1H, brs, H‐3), 4.41
(1H, s, 5‐OH), 5.00 (1H, s, H‐17a), 5.01 (1H, s, H‐17b), 6.15 (1H, d,
J = 10.2 Hz, H‐5), 8.60 (1H, s, H‐3′), 7.88 (2H, d, J = 8.5 Hz, H‐5′,
H‐8′), 7.54 (1H, t, J = 7.3 Hz, H‐6′), 7.60 (1H, t, J = 7.0 Hz, H‐7′),
7.96 (1H, d, J = 8.0 Hz, H‐10′), 8.05 (1H, d, J = 8.6 Hz, H‐11′). 13C‐
NMR (100.61 MHz, CDCl3): δ 13.3 (C‐20), 14.5 (C‐16), 16.3 (C‐19),
21.3 (C‐8), 25.9 (C‐10), 28.4 (C‐11), 29.0 (C‐18), 36.3 (C‐9), 37.6 (C‐
2), 49.3 (C‐1), 53.9 (C‐4), 71.4 (C‐5), 79.0 (C‐3), 114.7 (C‐17), 125.4
(C‐11′), 126.9 (C‐6′), 127.0 (C‐4′), 127.9 (C‐8′, C‐5′), 128.7 (C‐7′),
129.5 (C‐10′), 131.6 (C‐3′), 132.6 (C‐13), 135.3 (C‐2′), 135.8 (C‐9′),
144.2 (C‐6), 166.0 (C‐1′). ESI‐MS m/z 511 [M + Na]+, 527 [M + K]+.
12‐Hydroxyboetirane A (12): α½ 25D + 56 (c 0.100, CHCl3); 1H‐NMR
(400 MHz, CDCl3): δ 0.55 (1H, d, J = 9.1 Hz, H‐11), 0.65 (1H, m,
H‐9), 1.04 (3H, d, J = 6.6 Hz, CH3‐16), 1.07 (3H, s, CH3‐18), 1.15
(3H, s, CH3‐19), 1.22 (3H, d, J = 7.7 Hz, CH3‐20), 1.82 (1H, m,
H1α), 1.84 (1H, m, H‐7b), 1.91 (1H, m, H‐8a), 2.06 (1H, m, H‐8b),
2.12 (1H, m, H‐1β), 2.16 (1H, m, H‐2), 2.53 (1H, m, H‐7a), 2.74
(1H, m, H‐13), 3.11 (1H, dd, J = 3.2, 11.1 Hz, H‐4), 3.51 (1H, s, 3‐
OH), 3.91 (1H, brs, H‐3), 4.75 (1H, d, J = 9.4 Hz, H‐12), 4.92 (1H,
s, H‐17a), 5.09 (1H, s, H‐17b), 5.76 (1H, d, J = 11.1 Hz, H‐5), 7.54
(1H, t, J = 7.0 Hz, H‐6′), 7.60 (1H, t, J = 7.1 Hz, H‐7′), 7.87 (2H, d,
J = 8.5 Hz, H‐8′, H‐10′), 7.95 (1H, d, J = 7.8 Hz, H‐5′), 8.02 (1H, d,
J = 8.6 Hz, H‐11′), 8.58 (1H, s, H‐3′); 13C‐NMR (100.61 MHz, CDCl3):
δ 13.1 (C‐20), 13.5 (C‐16), 15.5 (C‐10, C‐19), 23.1 (C‐8), 26.6 (C‐11),
29.2 (C‐18), 30.3 (C‐9), 37.7 (C‐2), 38.3 (C‐7), 41.5 (C‐13), 44.2 (C‐1),
55.2 (C‐4), 70.8 (C‐5), 74.6 (C‐12), 75.0 (C‐3), 87.1 (C‐15), 116.0
(C‐17), 125.5 (C‐11′), 126.9 (C‐6′), 127.1 (C‐4′), 127.9 (C‐8′), 128.3
(C‐10′), 128.6 (C‐7′), 129.6 (C‐5′), 131.7 (C‐3′), 132.5 (C‐9′), 135.8
(C‐2′), 147.4 (C‐6), 168.1 (C‐1′), 220.1 (C‐14); ESI‐MS m/z 489 [M
– H2O + H]
+.2.5.4 | Preparation of euphoboetirane F (8)
Obtained from reaction of 4 (24 mg, 0.072 mmol) with 70 μL
(0.55 mmol) of propionic anhydride. The residue was purified by CC
(SiO2, 4 g, n‐hexane/EtOAc (1:0 to 0:1), Combiflash system) and pre-
parative TLC (n‐hexane/EtOAc 4:1, 2×) to give 16 mg (0.036 mmol,
50% yield) of a colourless oil. α½ 25D + 117 (c 0.100, CHCl3); 1H‐NMR
(400 MHz, DMSO): δ 0.80 (3H, d, J = 10.4 Hz, CH3‐16), 0.92 (3H,
t, J = 7.4 Hz, H‐3″), 1.01 (3H, t, J = 7.5 Hz, H‐3′), 1.10 (3H, s, CH3‐
19), 1.11 (1H, m, H‐8b), 1.16 (3H, s, CH3‐18), 1.16 (1H, m, H‐7b),
1.18 (1H, m, H‐9), 1.43 (1H, dd, J = 8.5, 11.6 Hz, H‐11), 1.50 (1H,
t, J = 12.4 Hz, H‐1β), 1.57 (3H, s, CH3‐20), 1.85 (1H, m, H‐8a), 2.08
502 NETO ET AL.(1H, m, H‐7a), 2.10 (2H, m, H‐2″), 2.14 (1H, m, H‐2), 2.30 (2H, m, H‐
2′), 2.55 (1H, dd, J = 2.9, 10.2 Hz, H‐4), 2.87 (1H, dd, J = 9.1, 11.9 Hz,
H‐1α), 4.69 (1H, s, H‐17a), 4.90 (1H, s, H‐17b), 5.34 (1H, s, H‐3), 5.93
(1H, d, J = 10.4 Hz, H‐5), 7.76 (1H, s, H‐12); 13C‐NMR (100.61 MHz,
DMSO): δ 8.7 (C‐3″), 9.0 (C‐3′), 12.4 (C‐20), 14.2 (C‐16), 16.3 (C‐19),
21.4 (C‐8), 25.1 (C‐10), 26.9 (C‐2″), 27.0 (C‐2′), 28.1 (C‐11), 28.6 (C‐
18), 34.8 (C‐9), 35.5 (C‐7), 37.0 (C‐2), 49.1 (C‐1), 52.5 (C‐4), 66.7 (C‐
5), 79.7 (C‐3), 87.4 (C‐15), 114.8 (C‐17), 133.2 (C‐13), 145.0 (C‐6),
152.5 (C‐12), 173.0 (C‐1″), 173.6 (C‐1′), 203.9 (C‐14); ESI‐MS m/z
469 [M + Na]+, 485 [M + K]+.2.5.5 | Preparation of euphoboetirane G (9)
Obtained from reaction of 4 (25 mg, 0.075 mmol) with 70 μL
(0.55 mmol) of diethylcarbamoyl chloride. The residue was purified
by CC (SiO2, 4 g, n‐hexane/EtOAc 1:0 to 0:1, CombiFash system) to
yield 24 mg (0.055 mmol, 73% yield) of an amorphous white solid.
α½ 25D + 64 (c 0.090, CHCl3); 1H‐NMR (400 MHz, CD3OD): δ 1.07
(3H, d, J = 6.7 Hz, CH3‐16), 1.11 (6H, m, H‐3′, H‐3″), 1.17 (3H, s,
CH3‐18), 1.18 (3H, s, CH3‐19), 1.25 (1H, m, H‐9), 1.47 (1H, dd,
J = 8.5, 11.7 Hz, H‐11), 1.56 (1H, dd, J = 10.5, 13.7 Hz, H‐1β), 1.64
(3H, s, CH3‐20), 1.80 (1H, m, H‐8a), 1.91 (1H, m, H‐8b), 2.04 (1H, m,
H‐7b), 2.07 (1H, m, H‐2), 2.34 (1H, m, H‐7a), 2.46 (1H, dd, J = 2.7,
10.6 Hz, H‐4), 3.07 (1H, t, J = 11.4 Hz, H‐1α), 3.17 (1H, m, H‐2″),
3.29 (1H, m, H‐2′), 4.10 (1H, s, H‐3), 4.67 (1H, s, H‐17a), 4.87 (1H, s,
H‐17b), 5.93 (1H, d, J = 10.5 Hz, H‐5), 7.60 (1H, brs, H‐12). 13C‐
NMR (100.61 MHz, CD3OD): δ 12.8 (C‐20), 13.5 (C‐3″), 13.8 (C‐3′),
14.2 (C‐16), 16.7 (C‐19), 22.9 (C‐8), 27.1 (C‐10), 29.2 (C‐18), 30.1
(C‐11), 35.9 (C‐7), 37.9 (C‐9), 39.1 (C‐2), 42.2 (C‐2′), 43.2 (C‐2″),
50.5 (C‐1), 55.8 (C‐4), 69.9 (C‐5), 80.6 (C‐3), 90.5 (C‐15), 114.1 (C‐
17), 135.7 (C‐13), 147.3 (C‐6), 154.3 (C‐12), 158.1 (C‐1′), 203.3 (C‐
14); ESI‐MS m/z 456 [M + Na]+, 472 [M + K]+.2.5.6 | Preparation of euphoboetirane H (10)
Obtained from reaction of 4 (17 mg, 0.052 mmol) with 70 μL
(0.74 mmol) of ethylchloroformate. The residue was purified by CC
(SiO2, 4 g, n‐hexane/EtOAc 1:0 to 0:1, CombiFash System) to obtain
5 mg (0.012 mmol, yield 23%) of a white amorphous solid. α½ 25D + 27
(c 0.090, CHCl3); IR (KBr) υmax cm
−1; 1H‐NMR (400 MHz, CDCl3): δ
1H‐NMR (400 MHz, CDCl3): δ 1.12 (3H, s, CH3–19), 1.16 (1H, m, H‐
8b), 1.18 (3H, s, CH3‐18), 1.20 (3H, d, J = 6.8 Hz, CH3‐16), 1.24 (3H,
t, J = 7.2 Hz, CH3‐3′), 1.25 (1H, m, H‐9), 1.49 (1H, dd, J = 8.3,
11.0 Hz, H‐11), 1.75 (1H, t, J = 13.2 Hz, H‐1β), 1.83 (3H, s, CH3‐
20), 1.99 (1H, m, H‐8a), 1.97 (1H, m, H‐7b), 2.18 (1H, m, H‐2),
2.46 (1H, t, J = 3.9 Hz, H‐4), 2.56 (1H, m, H‐7a), 3.38 (1H, dd,
J = 6.7, 13.1 Hz, H‐1α), 4.12 (2H, m, CH2‐2′), 4.49 (1H, t,
J = 3.6 Hz, H‐3), 5.46 (1H, d, J = 3.1 Hz, H‐5), 5.08 (1H, s, H‐
17a), 5.12 (1H, s, H‐17b), 6.39 (1H, d, J = 11.2 Hz, H‐12); 13C‐
NMR (100.61 MHz, CDCl3): δ 12.5 (C‐16), 12.6 (C‐20), 14.3 (C‐3′),
16.0 (C‐19), 22.6 (C‐8), 26.9 (C‐10), 28.7 (C‐11), 29.2 (C‐18), 33.8
(C‐7), 34.5 (C‐9), 37.8 (C‐2), 43.3 (C‐1), 48.3 (C‐4), 64.9 (C‐2′),74.1 (C‐5), 83.1 (C‐3), 90.4 (C‐15), 114.4 (C‐17), 132.8 (C‐13),
144.9 (C‐6), 145.6 (C‐12), 153.2 (C‐1′), 194.4 (C‐14); ESI‐MS m/z
407 [M + H]+.2.5.7 | Preparation of euphoboetirane I (11) and 12‐
hydroxyboetirane D (15)
Obtained from reaction of 4 (25 mg, 0.076 mmol) with 73 mg
(0.37 mmol) of 1‐adamantanecarbonyl chloride. The residue was puri-
fied by CC [SiO2, 15 g, n‐hexane/EtOAc (1:0 to 0:1)] and preparative
TLC (n‐hexane/EtOAc 4:1, 2×) to give 22 mg of 11 (0.044 mmol,
58% yield) and 5 mg of 15 (0.01 mmol, 13% yield) as amorphous white
solids. Euphoboetirane I (11): α½ 25D + 22 (c 0.100, CHCl3); 1H‐NMR
(400 MHz, CDCl3): δ 1.13 (3H, d, J = 4.4 Hz, CH3‐16), 1.13 (3H, s,
CH3‐18), 1.18 (3H, s, CH3‐19), 1.40 (1H, dd, d, J = 8.9, 11.1 Hz, H‐
11), 1.65–1.99 (15H, brs, H‐3′ to H‐11′), 2.00 (3H, s, H‐20), 2.13
(1H, m, H‐2), 2.42 (1H, d, J = 8.2 Hz, H‐4), 3.09 (2H, m, H‐1), 4.06
(1H, brs, H‐3), 4.35 (1H, s, H‐17a), 4.87 (1H, s, H‐17b), 5.72 (1H, d,
J = 9.4 Hz, H‐5); 1H‐NMR (400 MHz, DMSO): δ 0.94 (3H, d,
J = 6.8 Hz, CH3‐16), 1.08 (3H, s, CH3‐18), 1.12 (3H, s, CH3‐19), 1.13
(1H, m, H‐9), 1.39 (1H, dd, J = 8.6, 11.8 Hz, H‐11), 1.44 (1H, dd,
J = 11.2, 13.2 Hz, H‐1β), 1.54 (3H, s, CH3‐20), 1.62 (1H, m, H‐8a),
1.62 and 1.75 (12H, two brs, H‐3′, H‐5′, H‐7′, H‐8′, H‐10′, H‐11′),
1.79 (1H, m, H‐8b), 1.88 (1H, m, H‐7a), 1.89 (1H, m, H‐2), 1.91 (3H,
brs, H‐4′, H‐6′, H‐9′), 2.04 (1H, m, H‐7b), 2.28 (1H, dd, J = 1.8,
10.6 Hz, H‐4), 2.92 (1H, t, J = 10.8 Hz, H‐1α), 3.84 (1H, d,
J = 7.2 Hz, 3‐OH), 3.95 (1H, m, H‐3), 4.55 (1H, s, H‐17a), 4.81 (1H,
s, H‐17b), 5.48 (1H, s, 15‐OH), 5.99 (1H, d, J = 9.6 Hz, H‐5), 7.53
(1H, brs, H‐12); 13C‐NMR (100.61 MHz, CDCl3): δ 13.3 (C‐20), 14.6
(C‐16), 16.2 (C‐19), 19.0 (C‐8), 25.6 (C‐10), 28.0 (C‐4′, C‐6′, C‐9′),
29.9 (C‐18), 34.3 (C‐7), 36.1 (C‐9), 36.5 and 38.9 (C‐3′, C‐5′, C‐7′,
C‐8′, C‐10′, C‐11′), 37.1 (C‐2), 48.7 (C‐1), 55.6 (C‐4), 69.9 (C‐5),
77.8 (C‐3), 113.9 (C‐17), 135.1 (C‐13), 144.5 (C‐6), 178.1 (C‐1′); ESI‐
MS m/z 519 [M + Na]+, 535 [M + K]+.
12‐Hydroxyboetirane D (15): α½ 25D + 18 (c 0.100, CHCl3); 1H‐NMR
(400 MHz, CDCl3): δ 0.50 (1H, d, J = 9.2 Hz, H‐9), 0.59 (1H, m, H‐
11), 1.04 (3H, d, J = 4.4 Hz, H‐16), 1.04 (3H, s, H‐18), 1.10 (3H, s,
H‐19), 1.17 (3H, d, J = 8.0 Hz, H‐20), 1.68 and 1.85 (12H, two brs,
H‐3′, H‐5′, H‐7′, H‐8′, H‐10′, H‐11′), 1.80 (1H, m, H‐1α), 1.81 (1H,
m, H‐8b), 1.90 (1H, m, H‐8a), 1.84 (2H, m, H‐7), 2.00 (3H, brs, H‐4′,
H‐6′, H‐9′), 2.10 (1H, t, J = 12.6 Hz, H‐1β), 2.35 (1H, m, H‐2), 2.68
(1H, m, H‐13), 2.86 (1H, dd, J = 2.8, 11.2 Hz, H‐4), 3.46 (1H, s, 3‐
OH), 3.75 (1H, s, H‐3), 4.70 (1H, d, J = 9.2 Hz, H‐12), 4.70 (1H, s, H‐
17a), 4.96 (1H, s, H‐17b), 5.38 (1H, d, J = 11.2 Hz, H‐5); 13C‐NMR
(100.61 MHz, CDCl3): δ 13.1 (C‐20), 13.5 (C‐16), 15.4 (C‐19), 15.5
(C‐10), 23.0 (C‐8), 26.6 (C‐9), 28.0 (C‐4′, C‐6′, C‐9′), 29.2 (C‐18),
30.3 (C‐11), 36.6 and 38.9 (C‐3′, C‐5′, C‐7′, C‐8′, C‐10′, C‐11′), 37.7
(C‐2), 38.2 (C‐7), 41.5 (C‐13), 44.2 (C‐1, C‐2′), 55.2 (C‐4), 69.5 (C‐5),
74.5 (C‐12),74.9 (C‐3), 87.0 (C‐15), 115.4 (C‐17), 147.3 (C‐6), 179.6
(C‐1′), 220.1 (C‐14); ESI‐MS m/z 519 [M – H2O + Na]
+, 535 [M –
H2O + K]
+.
NETO ET AL. 5032.5.8 | Preparation of 12‐hydroxyboetirane B (13)
and 12‐hydroxyboetirane C (14)
Obtained from reaction of 4 (25 mg, 0.076 mmol) with 70 μL
(0.47 mmol) of 4‐(trifluoromethyl)benzoyl chloride. The residue was
purified by CC (SiO2, 10 g, n‐hexane/EtOAc (1:0 to 0:1) and prepara-
tive TLC (n‐hexane/EtOAc 4:1, 2×) to give 10 mg of 13 (0.019 mmol,
25% yield) and 11 mg of 14 (0.021 mmol, 28% yield) as white amor-
phous solids. 12‐Hydroxyboetirane B (13): α½ 25D + 35 (c 0.100, CHCl3);
1H‐NMR (400 MHz, CDCl3): δ 0.54 (1H, d, J = 9.2 Hz, H‐11), 0.63
(1H, m, H‐9), 1.01 (3H, d, J = 6.4 Hz, H‐16), 1.07 (3H, s, H‐18), 1.15
(3H, s, H‐19), 1.20 (3H, d, J = 8.0 Hz, H‐20), 1.68 (1H, m, H‐8b),
1.77 (1H, m, H‐1α), 1.81 (1H, m, H‐8a), 2.08 (1H, m, H‐1β), 2.12 (1H,
m, H‐7a), 2.26 (1H, m, H‐2), 2.50 (1H, m, H‐7b), 2.74 (1H, m, H‐13),
3.11 (1H, dd, J = 3.6, 10.5 Hz, H‐4), 3.98 (1H, d, J = 11.2 Hz, H‐5),
4.65 (1H, s, H‐17a), 4.79 (1H, d, J = 9.2 Hz, H‐12), 4.89 (1H, s, H‐
17b), 5.72 (1H, t, J = 3.2 Hz, H‐3), 7.72 (2H, d, J = 8.2 Hz, H‐4′),
8.20 (2H, d, J = 8.1 Hz, H‐3′); 13C‐NMR (100.61 MHz, CDCl3): δ
13.2 (C‐20), 13.9 (C‐16), 15.0 (C‐19), 15.4 (C‐10), 23.0 (C‐8), 26.9
(C‐11), 29. 1 (C‐18), 35.1 (C‐9), 37.6 (C‐2), 37.8 (C‐7), 41.7 (C‐13),
45.4 (C‐1), 56.6 (C‐4), 66.3 (C‐5), 74.7 (C‐12), 80.8 (C‐3), 86.7 (C‐15),
113.3 (C‐17), 121.5 (C‐6′), 125.7 (C‐4′), 130.3 (C‐3′), 133.2 (C‐5′),
134.8 (C‐2′), 151.1 (C‐6), 165.7 (C‐1′), 220.8 (C‐14); ESI‐MS m/z
507 [M – H2O + H]
+.
12‐Hydroxyboetirane C (14): α½ 25D + 38 (c 0.100, CHCl3); 1H‐NMR
(400 MHz, CDCl3): δ 0.53 (1H, d, J = 9.2 Hz, H‐11), 0.62 (1H, m, H‐
9), 1.02 (3H, d, J = 6.6 Hz, H‐16), 1.12 (3H, s, H‐18), 1.04 (3H, s, H‐
19), 1.20 (3H, d, J = 7.7 Hz, H‐20), 1.79 (1H, m, H‐1α), 1.84 (1H, m,
H‐1β), 1.90 (1H, m, H‐8a), 1.99 (1H, m, H‐2), 2.01 (1H, m, H‐8b),
2.15 (1H, m, H‐7a), 2.50 (1H, m, H‐7b), 2.73 (1H, m, H‐13), 3.07 (1H,
dd, J = 3.3, 11.2 Hz, H‐4), 3.88 (1H, t, J = 3.2 Hz, H‐3), 4.74 (1H, d,
J = 9.2 Hz, H‐12), 4.85 (1H, s, H‐17a), 5.06 (1H, s, H‐17b), 5.73 (1H,
d, J = 11.2 Hz, H‐5), 7.69 (2H, d, J = 8.2 Hz, H‐4′), 8.12 (2H, d,
J = 8.1 Hz, H‐3′); 13C‐NMR (100.61 MHz, CDCl3): δ 13.1 (C‐20),
13.5 (C‐16), 15.5 (C‐10, C‐19), 23.1 (C‐8), 26.6 (C‐11), 29.2 (C‐18),
30.3 (C‐9), 37.7 (C‐2), 38.3 (C‐7), 41.5 (C‐13), 44.1 (C‐1), 54.9 (C‐4),
71.3 (C‐5), 74.6 (C‐12), 75.1 (C‐3), 87.0 (C‐15), 116.2 (C‐17), 122.5
(C‐6′), 125.6 (C‐4′), 130.4 (C‐3′), 133.7 (C‐5′), 134.9 (C‐2′), 147.2 (C‐
6), 166.5 (C‐1′), 220.5 (C‐14). ESI‐MS m/z 507 [M – H2O + H]
+.2.6 | Biological assays
2.6.1 | Cell lines and cultures
L5178Y mouse T‐lymphoma cells (ECACC catalog no. 87111908, US
FDA, Silver Spring, MD, USA) were transfected with the pHa
MDR1/A retrovirus. The MDR1‐expressing cell line was selected by
culturing the infected cells with 60 ng/mL of colchicine (Sigma‐Aldrich
Chemie GmbH, Steinheim, Germany), to maintain the MDR phenotype
expression. L5178Y (parental, PAR) mouse T‐cell lymphoma cells and
the human MDR1‐transfected subline were cultured in McCoy's 5A
supplemented with 10% heat‐inactivated horse serum, 100 U/L L‐glutamine, and 100 mg/L penicillin/streptomycin mixture, all obtained
from Sigma Aldrich. The human colon adenocarcinoma cell lines
(Colo205 parental, and Colo 320/MDR‐LRP expressing MDR1), were
purchased from LGC Promochem, Teddington, UK. The cells were cul-
tured in RPMI 1640 medium supplemented with 10% heat‐inactivated
fetal bovine serum, 2 mM L‐glutamine, 1 mM sodium pyruvate and
100 mM HEPES. The semi‐adherent human colon cancer cells were
detached with 0.25% trypsin and 0.02% ethylenediaminetetraacetic
acid (EDTA) for 5 min at 37°C.
2.6.2 | Antiproliferative assays
The antiproliferative effects of all compounds were tested in a range
of decreasing concentrations using both mouse lymphoma and human
colon adenocarcinoma cell lines as experimental models. First, the
compounds were diluted in 100 μL of medium. The maximum tested
concentration of each compound was 100 μM. Then cells were dis-
tributed into 96‐well flat‐bottomed microtiter plates at concentrations
of 6 × 103 and 100 μL of medium were added to each well, with the
exception of medium and cell control wells. The microtiter plates were
initially incubated at 37°C for 72 h and, at the end of the incubation
period, 20 μL of MTT (thiazolyl blue tetrazolium bromide, Sigma‐
Aldrich Chemie GmbH) solution {5 mg/ml in phosphate‐buffered
saline (PBS)] was added to each well and incubated for another 4 h.
Then, 100 μL of 10% SDS (sodium dodecyl sulfate, Sigma) solution
[10% in 0.01 M hydrochloric acid (HCl)] was added into each well,
and the plates were further incubated overnight at 37°C. Cell growth
was determined by measuring the optical density (OD) at 550 nm (ref.
630 nm) with a Multiscan EX ELISA reader (Thermo Labsystems,
Cheshire, WA, USA). The percentage of inhibition of cell growth was
determined according to equation (1). All experiments were performed
in triplicate. The results were expressed as the mean ± standard devi-
ation (SD), and the half maximal inhibition concentration (IC50) values
were obtained by best fitting the dose‐dependent inhibition curves in




ODcell control −ODmedium control
 
× 100 (1)
2.6.3 | Rhodamine‐123 accumulation assay
Mouse T‐lymphoma cells or human colon adenocarcinoma cells were
adjusted to a density of 2 × 106 cells/mL, re‐suspended in serum‐free
McCoy's 5A medium or RPMI 1640, respectively, and distributed in
500 μL aliquots into Eppendorf centrifuge tubes. Then, 10 μL of test
compounds were added at two concentrations (2 or 20 μM) and
verapamil (positive control, EGIS Pharmaceuticals PLC, Budapest,
Hungary) was added at 20 μM. Dimethyl sulphoxide (DMSO) at 4%
was also added as solvent control. The samples were incubated for
10 min at room temperature, after which 10 μL of rhodamine‐123
(5.2 μM final concentration) were added. After 20 min of incubation
at 37°C the samples were washed twice, resuspended in 500 μL of
504 NETO ET AL.PBS and analysed by flow cytometry (Partec CyFlow Space Instru-
ment, Partec GmbH, Münster, Germany). The resulting histograms
were evaluated regarding mean fluorescence intensity (FL‐1), SD, both
FSC and SSC parameters, and the peak channel of 20000 individual
cells belonging to the total and the gated populations. The fluores-
cence activity ratio (FAR) was calculated on the basis of the quotient
between FL‐1 of treated/untreated resistant cell line (MDR1‐
transfected mouse lymphoma or Colo320 human colon adenocarci-
noma cells) over the respective treated/untreated sensitive cell line
(PAR mouse lymphoma or Colo205 human colon adenocarcinoma




2.6.4 | Drug combination assay
Doxorubicin (2 mg/mL, Teva Pharmaceuticals, Budapest, Hungary)
was serially diluted in the horizontal direction as previously described,
starting with 8 μg/mL. The resistance modifier was subsequently
diluted in the vertical direction, starting with 20 μg/mL. The dilutions
of doxorubicin were made in a horizontal direction in 100 μL, and the
dilutions of the resistance modifiers vertically in the microtiter plate in
50 μL volume. The cells were re‐suspended in culture medium and dis-
tributed into each well in 50 μL containing 1 × 104 cells, with the
exception of the medium control wells, to a final volume of 200 μL
per well. The plates were incubated for 48 h at 37°C in a CO2 incuba-
tor and at the end of the incubation period, the cell growth was deter-
mined by the MTT staining method, as described earlier. Drug
interactions were evaluated according to Chou using the CalcuSyn
v2.2 software.27 Each dose–response curve (for individual agents as
well as combinations) was fit to a linear model using the median effect
equation, in order to obtain the median effect value (corresponding to
the IC50) and slope (m). Goodness‐of‐fit was assessed using the linear
correlation coefficient, r, and only data from analysis with r > 0.90
were presented. The extent of interaction between drugs was
expressed using the combination index (CI), where CI = 1 represents
additive effect and CI > 1 antagonism. CI < 1 represents synergism
where 0.1 < CI < 0.3 = strong synergism; 0.3 < CI < 0.7 = synergism;
0.85 < CI < 0.9 = slight synergism.3 | RESULTS AND DISCUSSION
3.1 | Phytochemical study
Euphorbia boetica aerial parts were studied with the aim of finding
novel effective compounds for overcoming MDR in cancer cells.
Briefly, the powdered plant was exhaustively extracted with MeOH.
This crude residue was suspended in MeOH/H2O (1:1) and extracted
with EtOAc. The EtOAc soluble fraction was subjected to silica gel
flash chromatography to afford 10 crude fractions.8 Due to the high
complexity of these fractions, preliminary 1H‐NMR analysis wasperformed in order to prioritise those that were of the most interest.28
Although as complex as the spectra appeared, preliminary 1H‐NMR
spectra showed that fraction E, obtained with n‐hexane/EtOAc (7:3)
was very rich in macrocyclic diterpenes (Supporting Information,
Figure S1). Characteristic signals could be observed at δ 6.5–4.5,
which were assignable to olefinic protons and protons geminal to acyl
functions, found in macrocyclic diterpenes that generally appear as
polyesters. Moreover, it could also be recognised the signals for vinylic
and acetyl methyls displayed as singlets at δ 2.1–1.6, and other methyl
group signals at δ 1.2–0.7. Nevertheless, the isolation of macrocyclic
diterpenes is a difficult and laborious task since these compounds
often appear as a complex mixture of structurally related polyesters,
chlorophylls, triterpenes and steroids. In particular, the removal of
chlorophylls is amongst the most troublesome and time consuming
process in natural products isolation and purification. Several method-
ologies have been proposed to remove chlorophylls from crude
extracts or fractions, which include liquid–liquid partition, repeated
column chromatography, solid phase extraction using different adsor-
bents, or the use of activated charcoal that carries the risk of loss of
important compounds. Polyamide resins have been used to adsorb
apolar compounds, in batches or packed in chromatographic col-
umns.28 Therefore, in order to remove chlorophylls, fraction E was
subjected to a polyamide‐6 column chromatography eluted with mix-
tures of MeOH/H2O of decreasing polarity (1:1, 3:2, 7:3, 4:1 and
1:0). Fractions obtained with MeOH/H2O (3:2 and 7:3) contained
the bulk of diterpenes, as showed by a TLC analysis. As a result of
the removal of chlorophylls, it was possible to observe on the TLC
plates, the typical black or dark brown spots after spraying with
H2SO4/MeOH (1:1) followed by heating. Fractions eluted with
MeOH/H2O (4:1 and 1:0) were rich in chlorophylls and were studied
no further. This procedure allowed the straightforward isolation, in
larger amounts, of the new diterpene polyester euphoboetirane B (1)
and Euphorbia factor L15 (herein named euphoboetirane A, 2) that
was previously isolated from Euphorbia lathyris.25
Compounds 1 and 2 (Figure 1) were obtained as white crystals and
displayed very similar spectroscopic data. The 13C‐NMR and DEPT
spectra of euphoboetirane B (1) exhibited 27 signals corresponding
to: seven methyl groups, five methylenes, seven methines (two oxy-
genated at δC 65.9 and 80.1 and one olefinic at δC 146.8) and eight
quaternary carbons (two olefinic at δC 134.3 and 144.5, one oxygen-
ated at δC 92.5, one carbonyl at δC 197.0 and three ester carbonyl
groups at δC 169.9, 170.6 and 173.9). The
1H‐NMR spectrum showed
signals for four methyl groups: one secondary at δH 0.87 (d,
J = 6.7 Hz), two tertiary (δH 1.12 and 1.14) and one vinylic methyl
group displayed as singlet at δH 1.66. Two oxymethine protons (δH
5.57 t, J = 3.2 Hz; 6.05, d, J = 10.3 Hz) and three olefinic protons
(δH 4.70 s, 4.96 s; 6.46 d, J = 11.4 Hz) could also be observed. The
major difference between NMR data of compounds 1 and 2 was the
presence of signals corresponding to a propanoyl group in compound
1 (δH 2.32 m; 1.12 t, J = 7.4 Hz and δC 173.9, 27.9, 9.1) instead of an
acetyl group located at C‐3 in compound 2. The structure of 1 was
confirmed by 1H‐1H COSY, HMQC and HMBC experiments that
allowed the unequivocal assignment of all 1H and 13C signals. The
FIGURE 1 Chemical structures of lathyrane diterpenes (1 and 2) isolated from Euphorbia boetica aerial parts and preparation of 14β‐
hydroxylathyrane (3), lathyrol (4) and derivatives (5–15). Reagents and conditions: (i) LiAlH4, THF, 0°C, 1 h; (ii) KOH/MeOH (5%), room
temperature, 3 h; (iii) acylating reagent, DMAP (cat.), TEA/CH2Cl2 (1:1), room temperature or under reflux (60°C, nitrogen atmosphere), 2–18 h
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identical to those of euphoboetirane A (2)25 through a NOESY
spectrum.3.2 | Derivatives of lathyrol
Molecular derivatisation of macrocyclic diterpenes is regarded as an
important way to obtain a high number of homologous compounds
towards an increasing knowledge on structure–activity relationships
in P‐gp‐modulating activity. Therefore, in order to obtain a small set
of lathyrol derivatives and taking advantage of the chemical functions
of this compound, euphoboetirane B (1) was reduced, using LiAlH4,
and hydrolysed in a MeOH solution of KOH, to afford 14β‐
hydroxylathyrane (3), a new lathyrane‐type polyalcohol, and lathyrol
(4), respectively (Figure 1). Using lathyrol (4) as a starting material
and different acylation reagents, seven new derivatives were
obtained: three diacylated, named euphoboetiranes C, D and F (5, 6
and 8) and four monoacylated, named euphoboetiranes E, G and H(7, 9–11). While performing the referred reactions, some acylated
derivatives were further modified undergoing conjugate addition of
water to the α,β‐unsaturated system, giving rise to four new com-
pounds, named 12‐hydroxyboetiranes A–D (12–15), (Figure 1).
Lathyrol (4) was identified by comparison of its spectroscopic data
with those reported in the literature.26 14β‐Hydroxylathyrane (3) was
obtained as white amorphous powder with α½ 25D −134.0. The spectro-
scopic data of 3 resembled those achieved for lathyrol (4).26 As
expected, in the 1H‐NMR spectrum of 3, the most remarkable differ-
ence was the presence of a new singlet at δH 4.24 (H‐14). In the
13C‐NMR, the presence of a signal at δC 77.8 and the disappearance
of the ketone resonance at δC 207.1, together with the upfield shifts
of C‐12 (Δδ = −17.1 ppm), C‐13 (Δδ = −4.4 ppm) and C‐15
(Δδ = −3.4 ppm) were consistent with the introduction of a new
hydroxyl group at C‐14. The relative stereochemistry of all tetrahedral
centres was found to be identical to those of compound 1, except at
C‐14, the new tetrahedral centre. In this way, assuming the α‐
orientation for H‐4 as a reference point,26 the NOESY cross‐peaks
between H‐4/H‐2, H‐3/H‐2 and H‐2/H‐14 established the α‐
506 NETO ET AL.configuration of these protons. No correlation was found between H‐
4 and H‐5, which corroborated the preservation of the β‐configuration
for H‐5.
The structural elucidation of euphoboetiranes C‐I (5–11) was
achieved by comparison of their spectroscopic data with those of
lathyrol (4) and euphoboetirane A (1). However, it should be noted
that due to the poor spectral resolution of some compounds when dis-
solved in CDCl3, other solvents had also to be used to overcome this
problem, namely CD3OD, pyridine‐d5 and DMSO‐d6 (Supporting
Information).
Besides the signals due to the different acyl groups, the analysis of
1H‐NMR and 13C‐NMR spectra showed, as expected, very similar data
regarding the diterpenic core. When comparing with lathyrol (4), the
most remarkable differences in the 1H‐NMR spectrum were related
to the H‐3 and H‐5 chemical shifts that were displayed downfield
when these positions were acylated. These differences were in agree-
ment with the effects expected for the acylation of the hydroxyl
groups and were also observed in euphoboetirane B (1). Regarding
the 13C‐NMR spectra, it was crucial to analyse the carbonyl signals
in order to make conclusions on the number of acyl groups. The
location of the acyl groups was definitely confirmed by the long‐range
correlations between the carbonyl signals and the corresponding H‐3
and/or H‐5 oxymethine protons. The relative stereochemistry of all
tetrahedral centres was found to be identical to those of
euphoboetirane B (1).
When comparing the NMR spectroscopic data of 12‐
hydroxyboetiranes A–D (12–15) to those of the already described
ester derivatives 1, 2 and 5–11, several differences could be indi-
cated. Indeed, in the 1H‐NMR spectra of compounds 12–15 both
H‐12 and the olefinic methyl (CH3‐20) signal resonances disap-
peared, while new signals at δH 4.70–4.79 (t, J ≈ 9.2 Hz) and δH
1.17–1.22 (d, J ≈ 7.9 Hz) could be observed. Likewise, these differ-
ences were also obvious in the 13C‐NMR spectra, which showed the
presence of two extra methine carbons at δc ≈ 74.6 and δc ≈ 41.5,
together with the disappearance of the signals corresponding to the
olefinic carbons C‐12 and C‐13. Moreover, a downfield chemical
shift (Δδ + 23 ppm) was also observed for the ketone signal that
was in agreement with the absence of the α,β‐unsaturated system.
These structural features were confirmed by the analysis of 1H‐1H
COSY, HMQC and HMBC spectra that allowed the unambiguous
assignment of all proton and carbon resonances. These spectroscopic
data led to conclusion that 12‐hydroxyboetiranes A–D (12–15) dif-
fered from the remaining lathyrol derivatives by having a hydroxyl
group at C‐12 instead of the C‐12/C‐13 endocyclic double bond.
The relative configuration of 12‐hydroxyboetiranes A–D (12–15)
was deduced through the analysis of their NOESY spectra and by
comparison with euphoboetirane B (1), assuming, as usual, the α‐
orientation for H‐4. In this way, the strong nuclear Overhauser
interactions between H‐4/H‐3, H4/H‐2, H‐2/CH3‐18 and at CH3‐
18/H‐11 established the α configuration of these protons. The α‐
orientation of the new chiral centres C‐12 and C‐13 was supported
by nuclear Overhauser interactions between CH3‐18/H‐12, H‐12/
H‐11, H‐12/H‐13 and H13/H11. The β‐orientation of H‐5 wassuggested by the absence of a NOESY correlation between this pro-
ton and H‐4 and was corroborated by J4,5 value which were similar
to that of related diterpenes.25,263.3 | Biological activity
The diterpenes 1–15 were investigated for their antiproliferative
activity in order to select non‐cytototoxic concentrations to perform
the P‐gp modulation experiments. Antiproliferative assays were per-
formed using the MTT test on chemosensitive (PAR) and human
MDR1‐gene transfected mouse lymphoma cells (MDR), and on sensi-
tive and resistant human colon adenocarcinoma cell lines (sensitive
Colo205 and Colo320 MDR cells). The results are summarised in
Table 1 and expressed in IC50 values. The selectivity index
[SI = IC50(MDR cells)/IC50(PAR cells)] was also calculated. As can be
observed, except for euphoboetirane D (6) that showed an IC50 value
of 6.9 μM against Colo205 cell line, all compounds exhibited weak
antiproliferative activities (IC50 values higher than 10 μM). Moreover,
the compounds did not show significant IC50 disparities between the
assayed parental and MDR cell lines (SI values between 2.37 and
0.80), indicating that they were similarly active against both parental
and resistant cells.
The ability of compounds to modulate the transport activity of P‐
gp was evaluated on both human MDR1‐gene transfected L5178Y
mouse lymphoma and on MDR human colon adenocarcinoma cells.
Reversion of MDR was performed by flow cytometry, using a standard
functional assay that measures rhodamine‐123 (a fluorescent ana-
logue of the anti‐cancer drug doxorubicin) accumulation on the cells.
Verapamil (20 μM) was used as positive control, since it was a well‐
known MDR modifier. The compounds were tested at two concentra-
tions (2 and 20 μM). The FAR values were used to assess the P‐gp
modulating potential. Compounds were considered to be active when
presenting FAR values higher than 1, and assigned as strong P‐gp
modulators when FAR values are higher than 10.29,30 However, it
should be emphasised that FAR values obtained with L5178Y‐MDR
mouse lymphoma cells, where P‐gp is highly expressed, could not be
comparable with those obtained on human Colo320 MDR cells
because P‐gp expression is much lower on the latter.
The results are summarised inTable 2. As it can be observed, when
tested at 20 μM euphoboetiranes A (2), euphoboetiranes C–G (5–9)
and 12‐hydroxyboetiranes A–C (11–14) were found to be strong P‐
gp modulators on L5178Y‐MDR mouse lymphoma cells, displaying
FAR values ranging from 12.0 to 83.8. At this concentration, the stron-
gest effects were found for euphoboetiranes C (5, FAR = 83.8), D (6,
FAR = 82.2) and E (7, FAR = 64.7), which showed a manifold activity
when compared to that of verapamil (FAR = 17.7 at 20 μM). Compar-
ing the FAR values of the acylated diterpenes 5–11 and the parental
alcohol lathyrol (4, FAR = 2.0 at 20 μM), the majority of them showed
a 6 to 42‐fold increase of the activity. 14β‐Hydroxylathyrane (3) and
euphoboetirane B (1) were found to be barely active, even at the
highest concentration (FAR = 3.3 and 1.3, respectively).
TABLE 1 Antiproliferative activity of compounds 1–15 on mouse T‐lymphoma (L5178Y‐PAR and L5178Y‐MDR) cells and human colon ade-
nocarcinoma (Colo205 and Colo320) cells
Compound
L5178Y mouse T‐lymphoma cells Colon adenocarcinoma cells
IC50
a (μM) IC50 a (μM)
PAR MDR SI b Colo205 Colo320 SI b
Euphoboetirane B (1) 15.2 ± 2.4 18.2 ± 3.3 1.20 23.1 ± 4.1 25.4 ± 0.5 1.10
Euphoboetirane A (2) 18.6 ± 0.3 16.0 ± 2.0 0.86 55.0 ± 4.7 > 50 —
14β‐hydroxylathyrane (3) 60.7 ± 6.8 59.7 ± 3.4 0.98 > 50 65.1 ± 7.6 —
Lathyrol (4) 78.7 ± 2.7 62.8 ± 16.1 0.80 > 100 > 100 —
Euphoboetirane C (5) 27.6 ± 0.9 29.6 ± 1.2 1.07 15.3 ± 2.4 22.0 ± 0.4 1.44
Euphoboetirane D (6) 36.4 ± 1.0 45.7 ± 6.5 1.26 6.9 ± 0.4 16.4 ± 0.2 2.37
Euphoboetirane E (7) 40.9 ± 4.9 50.6 ± 0.4 1.24 11.2 ± 1.1 12.9 ± 1.2 1.15
Euphoboetirane F (8) 32.0 ± 2.4 45.4 ± 1.6 1.42 22.9 ± 3.2 24.6 ± 1.0 1.07
Euphoboetirane G (9) > 100 > 100 — 39.1 ± 4.9 58.7 ± 4.6 1.50
Euphoboetirane H (10) 37.0 ± 6.8 > 100 — > 100 > 100 —
Euphoboetirane I (11) 34.2 ± 1.6 49.4 ± 5.4 1.44 10.4 ± 0.6 12.7 ± 0.1 1.22
12‐Hydroxyboetirane A (12) 54.4 ± 3.8 > 100 — > 50 > 50 —
12‐Hydroxyboetirane B (13) 57.2 ± 2.2 70.5 ± 16.5 1.23 46.5 ± 3.2 47.9 ± 3.8 1.03
12‐Hydroxyboetirane C (14) 57.3 ± 4.0 > 100 — 55.8 ± 8.7 > 50 —
12‐Hydroxyboetirane D (15) 48.0 ± 2.8 52.2 ± 3.2 1.09 48.9 ± 4.6 > 50 —
DMSO (1%) > 100 > 100 — > 100 > 100 —
aValues of IC50 are the mean ± standard deviation of three independent experiments.
bSelectivity index (SI) = IC50 (MDR cells)/IC50 (PAR cells) or IC50 (Colo320 cells)/IC50 (Colo 320 cells).
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able reversion activity (FAR = 64.5). Moreover, at the lowest concen-
tration, euphoboetiranes C (5, FAR = 14.2), E (7, FAR = 13.3) and G (9,
FAR = 13.4) showed also significant MDR reversal activities (Table 2).
Concerning the activity on MDR human colon adenocarcinoma cells
(Colo320), euphoboetiranes A (2), C–F (5–8) and I (11), and 12‐
hydroxyboetiranes A–C (12–14) were the most effective, when tested
at 20 μM (FAR values between 3.1 and 4.9), although less active than
verapamil (FAR = 9.0). At 2 μM, the most active compounds were
euphoboetiranes D (5, FAR = 2.3) and E (7, FAR = 2.5).
Further studies were conducted in order to assess the combined
effect of diterpenes 1–15 and the anticancer drug doxorubicin, and
evaluate the type of interaction, using the checkerboard microplate
method on L5178Y‐MDR mouse lymphoma cells. The extent of inter-
actions between the anticancer drug and compounds 1–15 was calcu-
lated as proposed by Chou,27 and expressed using the CI values
(Table 3). All compounds had a synergistic interaction with the anti-
cancer drug (CI values among 0.19 and 0.86). Strong synergistic
effects were found for compounds 5, 6 and 8–13. Interestingly, the
majority of the most active compounds on the P‐gp modulation assay
were also those that developed higher synergism with doxorubicin.
However, the polyalcohols 3 and 4 also exhibited low CI values
(0.29 and 0.27, respectively) even though they displayed a weak P‐
gp modulation activity (FAR = 1.3 and 2.0 respectively, at 20 μM), sug-
gesting that different mechanisms may be involved in this process.
The drug combination assay was also applied on Colo320 cell linefor diterpenes 1, 2, 5–8 and 11–14, which revealed the highest
MDR in vitro modulation activities on the referred cell line. Curiously,
all compounds displayed a synergistic interaction, excepting
euphoboetiranes C (5) and E (7). In fact, diterpenes 5 and 7 showed
additive (CI = 0.95) and antagonistic effects (CI = 1.18), respectively,
despite being two of the most active modulators of P‐gp activity on
Colo320 cell line (FAR values 3.9 and 4.9, respectively, at 20 μM).
Regarding the chemical structure of the diterpenic core, the
analysed diterpenes could be divided in two main sets: compounds
with Δ6,17 and Δ12 double bonds (1–4, and 5–11, euphoboetirane
series) and compounds with an exocyclic Δ6,17 double bond and
absence of the Δ12 unsaturation, being hydroxylated at C‐12 (13–15,
12‐hydroxyboetirane series). Among the two sets, the compounds
differ in the type, number and location of the acyl groups. These struc-
tural features led to different physicochemical properties, such as lipo-
philicity, molecular volume and topological polar surface area, which
may condition the P‐gp modulatory ability of the compounds, and
were generally considered to be important non‐specific requirements
for MDR reversal activity.31,32 Nevertheless, the identification of spe-
cific structural characteristics of the different diterpenic scaffolds is
also of major importance to better understand structure–activity rela-
tionships in P‐gp modulation activity. Accordingly, our group reported
an improved pharmacophore model based on the analysis of several
in‐house macrocyclic diterpenes isolated from Euphorbia spe-
cies.10,33,34 In these studies, in silico approaches identified several
structural features that may correlate with experimental modulation
TABLE 2 Effect of compounds 1–15 on the P‐glycoprotein (P‐gp) mediated rhodamine‐123 efflux, on L5178Y‐MDR mouse T‐lymphoma cells
and on MDR human colon adenocarcinoma (Colo320)
Compound R1 R2 R3 Conc (μM)
FAR
L5178Y Colo320
Euphoboetirane B (1) 2 1.0 2.1
20 3.3 2.7
Euphoboetirane A (2) 2 4.6 1.8
20 23.7 3.5
14β‐hydroxylathyrane (3) — — — 2 0.9 1.3
20 1.3 1.5
Lathyrol (4) H H H 2 1.1 0.7
20 2.0 0.7
Euphoboetirane C (5) H 2 14.2 1.9
20 83.8 3.9
Euphoboetirane D (6) H 2 64.5 2.3
20 82.2 3.6
Euphoboetirane E (7) H H 2 13.3 2.5
20 64.7 4.9
Euphoboetirane F (8) H 2 3.0 1.7
20 57.2 4.1
Euphoboetirane G (9) H H 2 13.4 1.3
20 56.5 2.7
Euphoboetirane H (10) H H 2 1.2 0.8
20 1.9 1.6
Euphoboetirane I (11) H H 2 2.1 1.1
20 12.0 3.1
12‐hydroxyboetirane A (12) H H 2 2.5 1.6
20 44.0 4.4
12‐hydroxyboetirane B (13) H H 2 3.3 1.9
20 24.2 3.1
12‐hydroxyboetirane C (14) H H 2 1.8 1.8
20 36.1 3.4
(Continues)
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TABLE 2 (Continued)
Compound R1 R2 R3 Conc (μM)
FAR
L5178Y Colo320
12‐hydroxyboetirane D (15) H H 2 1.9 1.0
20 6.9 1.4
Verapamil 20 μM (positive control): FAR (L5178Y‐MDR cells) = 17.7, FAR (Colo320 cells) = 9.0; DMSO 2% (neg. control): FAR (L5178Y‐MDR cells) = 0.8, FAR
(Colo320 cells) = 0.6
TABLE 3 Type and strength of the interaction between compounds 1–15 and doxorubicin on L5178Y‐MDR mouse T‐lymphoma cells and on
MDR human colon adenocarcinoma (Colo320)
Compound
L5178Y‐MDR Colo320 cells
CI a Interaction CI a Interaction
Euphoboetirane B (1) 0.42 Synergism 0.52 Synergism
Euphoboetirane A (2) 0.32 Synergism 0.34 Synergism
14β‐hydroxylathyrane (3) 0.29 Strong synergism — —
Lathyrol (4) 0.27 Strong synergism — —
Euphoboetirane C (5) 0.22 Strong synergism 0.95 Additive
Euphoboetirane D (6) 0.16 Strong synergism 0.29 Strong synergism
Euphoboetirane E (7) 0.42 Synergism 1.18 Antagonism
Euphoboetirane F (8) 0.22 Strong synergism 0.39 Synergism
Euphoboetirane G (9) 0.20 Strong synergism — —
Euphoboetirane H (10) 0.19 Strong synergism — —
Euphoboetirane I (11) 0.25 Strong synergism 0.37 Synergism
12‐Hydroxyboetirane A (12) 0.29 Strong synergism 0.44 Synergism
12‐Hydroxyboetirane B (13) 0.25 Strong synergism 0.55 Synergism
12‐Hydroxyboetirane C (14) 0.86 Slight synergism 0.64 Synergism
12‐Hydroxyboetirane D (15) 0.44 Synergism — —
Data are shown as the best combination ratio between the tested compounds and doxorubicin.
aCombination index (CI) values at 50% of growth inhibition (ED50) were determined by using the CalcuSyn software to plot four to five data points to each
ratio. The extent of interaction between drugs was expressed using the CI. CI = 1 and CI > 1 represent additive effect and antagonism, respectively. CI < 1
represents synergism where 0.1 < CI < 0.3 = strong synergism; 0.3 < CI < 0.7 = synergism; 0.85 < CI < 0.9 = slight synergism.
NETO ET AL. 509of P‐gp. Therefore, the presence of a hydrophobic core, hydrogen
bond acceptor groups and one or two aromatic moieties was
highlighted as essential features for the interaction with P‐gp drug
binding site.10,33 Moreover, the conformation of the macrocyclic scaf-
fold, the charge distribution within the molecule and the acyl or
hydroxyl substitution patterns are also key factors for the biological
activity and considered to be responsible for the increased affinity
that some molecules display with P‐gp.34It is interesting to note that the most active diterpenes were those
with aromatic moieties (5–7, 12 and 14) exhibiting FAR values ranging
from 44.0 (12) to 83.8 (5) for L5178Y MDR cells and from 3.6 (6) to
4.9 (7) for Colo320 cells (at 20 μM). Euphoboetiranes C (5) and D (6)
are bioisosteric compounds, diacylated at C‐3 and C‐5, which differ
only by the presence of oxygen instead of a sulphur atom at the five
membered aromatic ring of the ester moieties. This fact clearly
changed the log P (5.3 vs. 6.5), topological polar surface area (116.2
510 NETO ET AL.vs. 89.9) and molecular volume (474 vs. 493) values, which seems to
contribute to the different MDR modulating activity, particularly evi-
dent when tested at low concentration (FAR = 14.2 for 5 and 64.5
for 6). When comparing the C‐5 naphtoyl derivatives, euphoboetirane
E (7) and 12‐hydroxyboetirane A (12), it can be noticed a decrease of
activity for compound 12 at both concentrations tested and on both
cell lines (Table 2). Surprisingly, euphoboetirane F (8), with two
propanoyl groups at C‐3 and C‐5 and euphoboetirane G (9) with a
carbamoyl function at C‐5, showed also a strong activity at 20 μM,
although not possessing any aromatic group.
According to these and previous results, macrocyclic diterpenes
possessing the lathyrane and jatrophane scaffolds have great potential
as P‐gp modulators on MDR cancer cells. Moreover, most of them,
when combined with antineoplastic drugs, such as doxorubicin, syner-
gistically enhance their effect, providing evidence that they may be
valuable as lead compounds and are worthy of further studies in order
to increase their potency and selectivity.
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